jdc wrote: ↑Fri Aug 13, 2021 4:53 pm
There's also the issue that Israel's data seems to be the most pessimistic available.
This
https://www.medrxiv.org/content/10.1101 ... 1.full.pdf gives 87% for Pfizer against symptomatic infections with Delta. This 88%
https://www.nejm.org/doi/full/10.1056/NEJMoa2108891 These figures are for the same outcome as the first Sinovac figure you gave, which was 58.49%
I'm assuming, btw, that the Sinovac data is for protection against Delta. If it isn't, then the use of the 39% figure for Pfizer is even more inappropriate.
The gamma variant was the most common in Chile during the period of the study, though it is now being replaced by the lambda variant.
The same Chilean study gave the following efficacy for the Pfizer vaccine:
Regarding the Pfizer-BioNTech vaccine, effectiveness results 14 days after the second dose, among a cohort of 4,500,000 individuals over the age of 16 affiliated to FONASA were:
87.69% effectiveness in preventing symptomatic COVID-19
97.15% effectiveness in preventing hospitalization
98.29% effectiveness in preventing ICU admission
100% effectiveness in preventing death
And for AstraZeneca:
Regarding the AstraZeneca vaccine, effectiveness results 14 days after the second dose, among a cohort of 2,380,000 individuals over the age of 16 affiliated to FONASA were:
68.68% effectiveness in preventing symptomatic COVID-19
100% effectiveness in preventing hospitalization
100% effectiveness in preventing ICU admission
100% effectiveness in preventing death
https://chilereports.cl/en/news/2021/08 ... -and-death
Here grows much rhubarb.